Faeth Therapeutics utilizes computational biology and machine learning to develop multi-nodal nutritional treatments that target cancer metabolism, inhibiting cell growth through a comprehensive understanding of metabolic pathways. This approach addresses the limitations of traditional therapies by expanding the range of druggable targets within the cancer metabolism landscape.
Funding
$80.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Traditional cancer treatments often target single pathways, leading to continued cell growth through intact alternative metabolic routes. The complexity of cancer metabolism makes it difficult to identify and target all relevant pathways effectively.
Solution
Faeth Therapeutics develops multi-nodal nutritional treatments that target cancer metabolism by employing computational biology and machine learning to understand and inhibit cancer cell growth. Their approach addresses the limitations of traditional therapies by expanding the range of druggable targets within the cancer metabolism landscape. By systematically analyzing the network of interconnected metabolic reactions, Faeth identifies comprehensive strategies to fully inhibit cancer cell growth, leveraging AI to navigate the complexities of cancer metabolism. This involves combining dual PI3K/AKT/mTOR inhibitors with insulin-suppressing diets, demonstrating tumor regression in preclinical models.
Target Audience
Faeth Therapeutics primarily targets patients with cancer, specifically those with solid tumors and metabolic dependencies, and the physicians and researchers who treat them.
Features
- Computational biology and AI-driven identification of key metabolic pathways driving cancer cell growth
- Development of multi-nodal treatment approaches to comprehensively inhibit cancer metabolism
- Focus on expanding available drug targets within the metabolic genome
- Clinical trials with patient support via the Faeth app for program adherence
- Combination therapies involving dual PI3K/AKT/mTOR inhibitors
- Integration of precision nutrition with targeted therapy
- Preclinical data demonstrating tumor regression in models of endometrial and breast cancer